Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Rahmat K. Sikder"'
Autor:
Philip H. Abbosh, Wafik S. El-Deiry, Erica R. McKenzie, Ali Behbahani, Alexander L. Metz, David J. Weader, Robert N. Uzzo, Moataz Ellithi, Rahmat K. Sikder
Figure S3: SW780 and RT4 cells are sensitized to cisplatin after the loss of p21. SW780 sg12A clone is more sensitive to cisplatin than sg109A clone, whereas in RT4, the sg12A and sg109a clones have similar sensitivities to cisplatin.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1bbe1a67d85ee11ad8f93f529caee8d
https://doi.org/10.1158/1541-7786.22513659.v1
https://doi.org/10.1158/1541-7786.22513659.v1
Autor:
Philip H. Abbosh, Wafik S. El-Deiry, Erica R. McKenzie, Ali Behbahani, Alexander L. Metz, David J. Weader, Robert N. Uzzo, Moataz Ellithi, Rahmat K. Sikder
Figure S1. A. sg12 successfully edited the CDKN1A gene in SW780 with high efficiency; chromatogram shows deletion of an adenine (A). B. Histograms from TIDE analysis of single-cell clones showed that the clones have largely homogeneous populations. F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d23031e9d849caade2e9b48314d380
https://doi.org/10.1158/1541-7786.22513662.v1
https://doi.org/10.1158/1541-7786.22513662.v1
Publikováno v:
Curr Opin Urol
Purpose of review The purpose of this review is to examine and evaluate similarities and differences in bladder cancer expression subtypes and to understand the clinical implications of the molecular subtyping. Recent findings Four independent classi
Autor:
David J. Weader, Alexander L. Metz, Robert N. Uzzo, Ali Behbahani, Wafik S. El-Deiry, Moataz Ellithi, Philip Abbosh, Rahmat K. Sikder, Erica R. McKenzie
Publikováno v:
Mol Cancer Res
Muscle-invasive bladder cancer (MIBC) frequently harbors mutations in the CDKN1A gene, which encodes the tumor suppressor protein p21, with the majority of alterations truncating the peptide. The effect of these mutations is poorly understood. We hyp
Autor:
Rahmat K. Sikder, Randy W. Lesh, Peter J. Huwe, Sanjeevani Arora, Sanat Deshpande, Michael J. Hall, Amanda J. Browne, Erica A. Golemis, Roland L. Dunbrack, Manali Shah, Emmanuelle Nicolas
Publikováno v:
Cancer Biology & Therapy. 18:519-533
The cancer-predisposing Lynch Syndrome (LS) arises from germline mutations in DNA mismatch repair (MMR) genes, predominantly MLH1, MSH2, MSH6, and PMS2. A major challenge for clinical diagnosis of LS is the frequent identification of variants of unce
Autor:
Philip Abbosh, Michael L. Stromyer, Wiley J. Youngs, Jessi A. Baughman, Marie R. Southerland, Uttam Satyal, Rahmat K. Sikder, David J. Weader
Publikováno v:
Eur J Med Chem
Imidazolium salts have shown great promise as anticancer materials. A new imidazolium salt (TPP1), with a triphenylphosphonium substituent, has been synthesized and evaluated for in vitro and in vivo cytotoxicity against bladder cancer. TPP1 was dete
Autor:
Rahmat K. Sikder, Prashanth Gokare, Philip Abbosh, Paulo R. Del Valle, Amriti R. Lulla, Xiaobing Tian, Wafik S. El-Deiry, Shengliang Zhang, Liz J. Hernandez Borrero
Publikováno v:
Cancer research. 78(10)
Kim and colleagues reported a p53/p21 complex regulates cancer cell invasion and apoptosis by targeting the Bcl-2 family ([1][1]). Interaction of overexpressed p53 and p21 proteins in p53-null H1299 cells correlated with decreased cell invasion. No c
Publikováno v:
Cancer Research. 78:405-405
Introduction Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and is driven by loss of chromosome 3p. The 3p tumor suppressor PBRM1 is mutated in about 1/3 of tumors. VHL loss is well-known to drive the hypoxic respons
Autor:
Philip Abbosh, Shengling Zhang, Avital Lev, Rahmat K. Sikder, Amriti R. Lulla, Xiaobing Tian, Wafik S. El-Deiry, David T. Dicker
Publikováno v:
Cancer Research. 78:3954-3954
The tumor-suppressor p53 prevents cancer development via initiating cell-cycle arrest, cell death, repair, or anti-angiogenesis processes. Over 50% of human cancers harbor cancer-causing mutations in p53. p53 mutations not only abrogate its tumor-sup
Publikováno v:
Cancer Research. 78:2307-2307
Introduction Approximately 15% of muscle invasive bladder cancers harbor mutations in the CDKN1A gene, which encodes the p53 target gene p21, with the majority of alterations truncating the peptide. We previously found that proximal truncation of p21